(via TheNewswire)

The U.S. patent applications cover proprietary combinations of NeuroThera’s PEA technology with LSD, ketamine and ibogaine for potential therapeutic applications, including mental health disorders, such as depression and PTSD as well as substance use disorders

Toronto, Ontario – TheNewswire - September 23, 2026 – NeuroThera Labs Inc. (TSXV: NTLX) (the " Company " or " NeuroThera "), a clinical-stage pharmaceutical company, today highlighted the expansion of the U.S. intellectual property portfolio through its ongoing collaboration with Clearmind Medicine Inc. (“ Clearmind ”) (Nasdaq: CMND).

As part of the collaboration, three U.S. patent applications have been published covering novel combinations of lysergic acid diethylamide (“LSD”), ketamine and ibogaine with N-acylethanolamines, including palmitoylethanolamide (“PEA”), NeuroThera’s proprietary technology.

The applications cover potential therapeutic uses across a range of indications, including mental health disorders such as depression and post-traumatic stress disorder, as well as pain and substance use disorders.

These U.S. patent applications build on previously announced intellectual property generated through the collaboration, including a U.S. patent application covering the combination of MDMA and N-acylethanolamines for potential treatment of PTSD, anxiety and eating disorders.

The continued maturation of the patent portfolio reflects the broader potential applications of NeuroThera’s PEA technology when combined with psychoactive compounds such as psychedelic compounds. The Company believes that these combinations may support the development of novel therapeutic approaches across multiple neuropsychiatric and substance use disorder indications.

NeuroThera and Clearmind continue to advance their collaboration, aimed at bringing safer and more effective treatments to market for some of the most common and rapidly growing mental ‑ health conditions. The companies remain focused on combining PEA with psychedelic ‑ derived compounds, while enhancing the intellectual property portfolio supporting these innovative therapeutic programs

About NeuroThera Labs Inc.

NeuroThera Labs Inc. (TSXV: NTLX) is a clinical-stage pharmaceutical company focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations.

For further information, please contact:

Michal Efraty

IR Manager

NeuroThera Labs Inc.

Telephone: +972-3-7617108

Email: michal@efraty.com

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Notice on Forward-Looking Statements

This news release contains statements that constitute "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking information and are based on expectations, estimates and projections as at the date of this news release. Forward-looking information can often be identified by words such as "may," "potential," "could," "expects," "anticipates," "intends," "believes" and similar expressions.

Forward-looking information in this news release includes, without limitation, statements regarding:

the potential therapeutic uses of NeuroThera’s product candidates across a range of indications, the broader potential applications of NeuroThera’s PEA technology, the potential of NeuroThera and Clearmind to bring safer and more effective treatments to market for some of the most common and rapidly growing mental ‑ health conditions, and continued enhancement of the intellectual property portfolio supporting these innovative therapeutics .

Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those expressed or implied. Such factors include, without limitation: the risk that the patent applications may not be granted or otherwise challenged ; the risks that potential therapeutic benefits of NeuroThera’s product candidates across a range of indications may not be realized; the risk that NeuroThera’s PEA technology may not be successful in achieving broader potential applications; the risk that NeuroThera and Clearmind may not be able to demonstrate safety or efficacy in future clinical trials; the Company's ability to obtain, maintain, expand and enforce intellectual property protection ; the Company's need for additional financing to complete the clinical development program and the risk that such financing will not be available on acceptable terms, or at all; competition from other companies developing treatments , some of which have substantially greater resources or are at more advanced stages of development; geopolitical, security and other conditions in Israel ; and general economic, market and business conditions, and the risks described in the Company's continuous disclosure documents filed on SEDAR+ ( www.sedarplus.ca ).

Readers are cautioned that the foregoing list of factors is not exhaustive. These statements are not guarantees of future performance and undue reliance should not be placed on them. The Company does not undertake any obligation to update or revise any forward-looking information, except as required by applicable securities laws.

Copyright (c) 2026 TheNewswire - All rights reserved.